急性或近期HIV感染立即与推迟24周启动ART的随机临床研究
在秘鲁利马男男性行为者和跨性别女性中开展的开放标签随机临床研究,216例急性或近期HIV感染者随机接受立即或推迟24周启动ART。立即治疗组非ART相关不良事件发生率更低,且启动ART距估计可检测感染日期的天数越短,CD4/CD8比值和免疫标志物模式越优。
要点
- 急性或近期HIV感染立即启动ART可降低非ART相关不良事件发生率。
- 启动ART距EDDI≤30天者CD4/CD8比值优于>90天者。
- 免疫标志物模式在>90天启动者与≤30天或≤90天启动者间存在差异。
核心结论
- 急性或近期HIV感染立即启动ART较推迟24周可降低非ART相关不良事件发生率,且更早启动与更优免疫恢复相关。
研究设计与样本
- 开放标签随机临床研究,在秘鲁利马纳入216例成人男男性行为者和跨性别女性急性或近期HIV感染者,随机分为立即启动ART组(105例)和推迟24周启动组(111例)。
临床怎么用
- 对于急性或近期HIV感染者,应尽早启动ART以降低非ART相关不良事件并改善免疫恢复。
局限性
- 原文未报告针对急性HIV的WHO推荐条款的具体修订内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In addition to demonstrated public health benefits on reducing transmission, it remains unclear how early antiretroviral therapy (ART) must be started after acquisition of human immunodeficiency virus (HIV) to maximize individual benefits. METHODS: We conducted an open-label randomized clinical study in Lima, Peru among adult men who have sex with men and transgender women with acute (HIV-antibody negative/HIV-1 RNA positive) or recent (confirmed negative HIV-antibody or RNA test within 3 months) HIV infection, who were randomized to start ART immediately versus defer by 24 weeks. We evaluated outcomes by treatment arm and immunologic markers by days since estimated date of detectible infection (EDDI). RESULTS: Of 216 participants, 105 were assigned to immediate arm and 111 to deferred arm (median age 26.8 years, 37% with acute HIV). The incidence of non-ART-related adverse events was lower in immediate versus deferred arm (83 vs 123/100 person-years, IRR 0.67 (95% confidence interval [CI] .47, .95; P = .02), the difference dominated by fewer infections in those treated immediately. After 24 weeks of ART, between-group differences in CD4/CD8 cell ratio lessened (P = .09 overall), but differences between those initiating ART ≤ 30 days from EDDI (median 1.03, interquartile range [IQR] 0.84, 1.37), and those initiating > 90 days (0.88, IQR 0.61, 1.11) remained, P = .02. Principal components analysis of 20 immune biomarkers demonstrated distinct patterns between those starting ART > 90 days from EDDI versus those starting within 30 or 90 days (both P < .001). CONCLUSIONS: To our knowledge, this is the only evaluation of randomized ART initiation during primary HIV and provides evidence to explicitly consider acute HIV in World Health Organization recommendations for universal ART. CLINICAL TRIALS REGISTRATION: NCT01815580.
引用
- Lama JR, Ignacio RAB, Alfaro R, et al. Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The Sabes Randomized Clinical Study. Clin Infect Dis. 2021. PMID: 32107526. doi:10.1093/cid/ciaa167
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。